Kelsey Financial LLC Makes New $7.13 Million Investment in Amgen Inc. $AMGN

Key Points

• Kelsey Financial LLC acquired a new position in Amgen (AMGN), buying 21,796 shares worth approximately $7.13 million, making AMGN about 6.1% of Kelsey's holdings and its sixth-largest position.
• Amgen beat Q4 estimates with EPS of $5.29 (vs. $4.76 expected) and revenue of $9.87B (vs. $9.46B), and set FY2026 guidance at EPS 21.600–23.000.
• Analysts are mixed: MarketBeat shows a consensus rating of "Hold" with an average price target of $355.84, though several firms have recently raised their targets (e.g., Wells Fargo to $390, Citigroup to $345).

Kelsey Financial LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,796 shares of the medical research company's stock, valued at approximately $7,134,000. Amgen comprises approximately 6.1% of Kelsey Financial LLC's holdings, making the stock its 6th largest position.

Several other institutional investors have also recently bought and sold shares of AMGN. Brighton Jones LLC raised its holdings in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after buying an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company's stock worth $331,000 after buying an additional 114 shares during the last quarter. Schnieders Capital Management LLC. raised its holdings in Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company's stock worth $7,220,000 after buying an additional 5,853 shares during the last quarter. Main Street Financial Solutions LLC raised its holdings in Amgen by 11.3% during the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company's stock worth $1,141,000 after buying an additional 416 shares during the last quarter. Finally, Ieq Capital LLC raised its holdings in Amgen by 5.1% during the second quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company's stock worth $15,120,000 after buying an additional 2,611 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Analysts Set New Price Targets

AMGN has been the topic of several research reports. Wells Fargo & Company upped their price objective on shares of Amgen from $375.00 to $390.00 and gave the stock an "equal weight" rating in a report on Thursday, March 19th. Citigroup increased their target price on shares of Amgen from $315.00 to $345.00 and gave the company a "neutral" rating in a report on Wednesday, February 4th. Rothschild & Co Redburn increased their target price on shares of Amgen from $180.00 to $200.00 and gave the company a "sell" rating in a report on Wednesday, February 18th. Weiss Ratings reiterated a "buy (b)" rating on shares of Amgen in a report on Monday, December 29th. Finally, Mizuho increased their target price on shares of Amgen from $280.00 to $295.00 and gave the company an "outperform" rating in a report on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Amgen presently has an average rating of "Hold" and a consensus price target of $355.84.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: China approval for tarlatamab expands Amgen’s lung-cancer market access and supports future revenue in a large oncology market — a meaningful commercial win for a new oncology asset. Amgen's lung cancer drug tarlatamab wins China approval
• Positive Sentiment: Phase‑4 FORWARD II gout study update: a less‑frequent Krystexxa dosing schedule could improve patient adherence and lifetime drug value, which would be positive for product uptake and revenue stability. Amgen’s FORWARD II Gout Study
• Positive Sentiment: Analyst bullishness on fundamentals: Zacks argues Amgen is poised to beat earnings again, supported by its recent history of surprise results and solid guidance — this can underpin near‑term sentiment ahead of the next report. Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
• Positive Sentiment: Royal Bank of Canada raised its price target to $370, signaling upside from some institutional analysts and suggesting conviction in Amgen’s mid‑term growth drivers. Royal Bank Of Canada Increases Amgen Price Target
• Neutral Sentiment: Guggenheim nudged its target to $351 while retaining a neutral rating — little immediate directional impact given the price is near that level. Amgen Price Target Raised to $351 at Guggenheim
• Neutral Sentiment: Short‑interest data reported for April appears inconsistent/erroneous (reads as 0 shares / NaN increase), so it’s unlikely to be a reliable driver of today’s action. (data entry)
• Neutral Sentiment: Media pieces highlighting Amgen’s profitability and recent TEPEZZA subcutaneous Phase‑3 topline results reinforce the company’s longer‑term value story but are incremental to near‑term price moves. Is Amgen One of the Most Profitable Value Stocks?
• Negative Sentiment: Morgan Stanley’s latest stance (equal‑weight, target raised only to $326) and other hold ratings emphasize limited near‑term upside vs. current levels — that analyst positioning is weighing on the stock. Morgan Stanley equal weight on Amgen

Amgen Price Performance

AMGN opened at $350.92 on Friday. The firm has a market cap of $189.39 billion, a P/E ratio of 24.66, a PEG ratio of 3.48 and a beta of 0.47. The firm has a 50-day moving average of $363.87 and a 200 day moving average of $335.08. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm's revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen's dividend payout ratio is presently 70.84%.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.